The downward movement in Bristol-Myers Squibb’s shares is primarily driven by a high-profile Wall Street downgrade that eroded investor confidence in the company’s mid-to-late-stage drug pipeline. Leerink Partners lowered its rating on the pharmaceutical giant to a market perform stance while substantially cutting its target price. Analysts highlighted heightened execution risks and lower conviction ahead of critical clinical readouts over the coming months, leading to reduced long-term revenue and earnings projections for key pipeline candidates.

This analyst action amplifies long-standing structural anxieties regarding the company’s growth trajectory. Investors remain sensitive to upcoming patent cliffs for core commercial franchises,…